Janney Montgomery Scott LLC Sells 2,218 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Janney Montgomery Scott LLC lessened its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 10.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,850 shares of the company’s stock after selling 2,218 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Tarsus Pharmaceuticals were worth $1,044,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its holdings in Tarsus Pharmaceuticals by 16.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Creative Planning acquired a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $362,000. Vestal Point Capital LP bought a new position in shares of Tarsus Pharmaceuticals in the third quarter valued at $7,565,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at about $3,590,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

NASDAQ TARS opened at $56.94 on Thursday. The company has a market capitalization of $2.18 billion, a PE ratio of -14.94 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The company has a 50-day simple moving average of $51.95 and a 200 day simple moving average of $40.42.

Wall Street Analyst Weigh In

TARS has been the topic of several recent research reports. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Barclays upped their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a report on Monday, January 27th. Finally, The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $56.00.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.